New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:13 EDTVVUS, AUXLVIVUS and Auxilium announces FDA accepted STENDRA's supplemental application
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has accepted a supplemental application that proposes to revise the STENDRA, or avanafil, prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with Erectile Dysfunction." The PDUFA date for the supplemental filing is September 20.
News For VVUS;AUXL From The Last 14 Days
Check below for free stories on VVUS;AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
07:03 EDTVVUSVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 21, 2014
09:07 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTAUXLAuxilium announces positive data from Phase 2a study of CCH with cellulite
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use